Industry Veterans Bruce Perkins and Mark Vachon Join Global Nephrology Solutions Executive Board

TEMPE, Ariz.–(BUSINESS WIRE)–Global Nephrology Solutions (“GNS”), one of the largest physician-led and physician-owned kidney care platforms in the United States, today announced the addition of two new board members to the rapidly growing organization. The news comes on the heels of the addition of six new members of the organization’s leadership team, positioning GNS for further growth and allowing the company to serve and scale its best-in-class kidney care delivery platform to independent nephrologists.

Leaders joining the GNS Board include:

• Bruce Perkins – Perkins is an experienced board member with a demonstrated history of working in healthcare delivery, finance and services. He is highly adept in working with physician practices, payors, home health/hospice, pharmaceuticals, Medicare Advantage, and fee for service medicine. For 38 years, he served in various roles at Humana, leading hospitals and health plans, and organically building the Healthcare Services segment of Humana, a 20-billion-dollar business. Perkins is currently the managing member for Perkins, Smith & Associates, L.L.C., a healthcare consulting firm based in Louisville, Kentucky. He serves on the board of Amedisys, Advanced Dermatology and Cosmetic Surgery, Devoted Health, Physician’s Endoscopy and Remedi SeniorCare, as well as in strategic advisory roles for myNEXUS, ChenMed, the Marwood Group, US Imaging, Matrix Medical Network and Magellan Health, Inc.
• Mark Vachon – Vachon is a Fortune 10 C-level executive with a 30-year career spearheading global business transformation, fueling innovation, igniting profits, and accelerating growth primarily across multi-billion-dollar GE businesses. Currently, Mr. Vachon serves on the boards of bluebird bio, a publicly traded gene and cell therapy company; Numotion, the national leader in complex rehab technology services; Klockner Pentaplast, a Luxembourg based packaging business; Beacon Mobility, a leading provider of mobility services in the US; and chairs the board of the Charitable Health and Retirement Trust in Boston. Prior to retiring in 2012 Mr. Vachon assumed a variety of leadership positions across the General Electric organization. Mr. Vachon was President and CEO of GE Healthcare Americas from 2009 to 2010, and prior to that, he was President and CEO of Global Diagnostic Imaging, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was Executive Vice President and CFO at GE Healthcare. A two-time recipient of the Chairman’s Leadership Award, he was named a Company Officer by then Chairman and CEO Jack Welch in 1999 and member of GE’s Corporate Executive Council in 2006.

“We are honored to welcome well-respected industry leaders Mark and Bruce whose expertise will serve our physician partners and help strengthen our platform’s capabilities during a dynamic time for our industry,” said Rajiv Poduval, MD, FASN, Founding Chief Executive Officer of Global Nephrology Solutions. “They will further our mission of empowering physicians, enabling them to stay independent, relevant, and at the center of patient-care delivery. It is through this endeavor that we will have a meaningful, positive impact on the delivery of kidney care in a value-based market.”

GNS, which announced a partnership with Audax Private Equity (“Audax”) in January 2021, is a national platform of more than 350 providers and 800 employees providing the complete continuum of kidney care across 10 states. GNS aims to rapidly grow its network over the next year in order to advance its pursuit of the quadruple aim of delivering cost-effective care, improving patient outcomes, and enhancing both the patient and physician experience.

The GNS value-based care delivery platform is driven by proprietary, predictive data analytics and clinical workflows underpinned by one of the world’s largest clinical chronic kidney disease (“CKD”) data warehouses that enable nephrologists to deliver better patient outcomes and value-based care. Building on its deep value-based experience with and participation in CMMI ESCO models, on January 1, 2022, GNS will launch CKCC value-based operations in four markets with over 10,000 covered lives, representing over $600 million of medical expense under management.

About Global Nephrology Solutions

GNS is one of the nation’s leading physician-led nephrology organizations, with more than 350 providers and 800 employees, supporting nephrologists who provide care across 10 states. The company remains committed to keeping nephrologists independent, relevant, and at the center of patient-care delivery. The GNS value-based care delivery platform is driven by proprietary, predictive data analytics supported by one of the world’s largest clinical chronic kidney disease data (“CKD”) warehouses that enables nephrologists to deliver better patient outcomes and value-based care. For more information, visit the Global Nephrology Solutions website at www.globalnephrologysolutions.com.

Contacts

Emily Shirden

248-802-3202

eshirden@jarrardinc.com